The IVW results indicated that HMGCR inhibition decreased the risk of CHD: Per 1 standard deviation (SD, mg/dL) decrease in low-density lipoprotein cholesterol (LDL-C) was associated with a 29.3% reduction in CHD risk (GWAS ID: ieu-a-7) (odds ratio (OR) = 0.707; 95% confidence interval (CI) = 0.595–0.806; P = 2.179 × 10−6), and 40.9% reduction in CHD risk (GWAS ID: ebi-a-GCST000998) (OR = 0.591; 95% CI = 0.460–0.759; P = 4.015 × 10−5), respectively. Here, HMGCR is linked to coronary artery disorder.